The Clinical Efficacy Of Sanxian Tang Combined With MFOLFOX6 Middle-late Stage Spleen-kidney Yang Deficiency Colon Cancer

Objective : Through a comparative study with a control group using the mFOLFOX6 chemotherapy regimen alone,the clinical efficacy and safety of Sanxian tang combined with mFOLFOL6 regimen for patients with colon-intestine carcinoma of spleen-kidney yang deficiency were observed and objectively evaluated in terms of clinical efficacy and laboratory data.The analysis of the theoretical sources and basis of the use of drugs and the selected drugs will provide new ideas and objective evidence for improving the quality of life of patients with colon cancer in the middle and late stages.Methods:According to the principle of randomized comparison in clinical trials,60 patients with clinically diagnosed spleen-kidney yang type colon cancer were selected and randomly divided into two groups: 30 in the control group and 30 in the treatment group.In terms of treatment,Control group: oxaliplatin 85mg/m2 intravenous drip 2 hours d1 + LA 400mg/m2 intravenous drip 2 hours d1 + 5-FU 400mg/m2 intravenous injection,and then 1200mg/m2 x 2 continuous intravenous infusion(total 2400mg/m2,continuous infusion for 46-48 hours,repeated every 2 weeks.Treatment group: oxaliplatin 85mg/m2 intravenous infusion 2 hours d1 + LA 400mg/m2 intravenous infusion 2 hours d1 + 5-FU 400mg/m2 intravenous injection,and then 1200mg/m2 x 2 continuous intravenous infusion(total 2400mg/m2,continuous infusion for 46-48 hours,repeated every 2 weeks.Sanxian Tang is taken orally during chemotherapy,once a day,one bag at a time.Both groups took 8 weeks as a course of treatment and observed one course of treatment.Firstly,before and after treatment,all clinical patients were examined for blood routine,liver and kidney function,and lymphocyte subsets.Secondly,TCM syndrome scores were compared before and after treatment.All data were analyzed using SPSS.22.0 statistical software.The study was withdrawn when there was drug allergy or could not tolerate chemotherapy during the study.Results:There was no statistical difference between the two groups in terms of age,gender,and other general data before treatment.There was comparable between the two groups(P>0.05).Serum CEA,CA199,TCM syndrome scores,and KPS scores were not statistically significant between the two groups before treatment.Differences,comparable(P>0.05).After one course of clinical treatment,(1)There was a statistically significant difference between the two groups before and after treatment with CEA and CA199(P<0.05).There was no difference between the two groups(P>0.05).(2)Within the TCM syndrome score group,there was a significant decrease after treatment,and there was a statistically significant difference between the two groups(P<0.01).The improvement of the TCM syndrome scores between the two groups was statistically significant(P<0.01).(3)The efficacy evaluation of TCM syndromes showed that the total effective rate was 89% in the treatment group and 76.67% in the control group.The curative effect in the treatment group was better than that in the control group,and the difference was statistically significant(P<0.01).Conclusion : The combined use of traditional Chinese medicine Sanxian Decoction and mFOLFOX6 can reduce the myelosuppression of chemotherapy and improve the patient’s immunity.It is superior to chemotherapy alone in the treatment of patients with advanced colon cancer,especially in improving TCM symptoms and survival of patients with cancer.The improvement of the quality and the reduction of the lymphocyte decrease caused by chemotherapy and the side effects of other chemotherapy have obvious curative effect and high safety.